This cross-sectional analysis of baseline data from the EMTICS cohort examined real-world pharmacological treatment patterns in 709 children and adolescents (ages 3–16) with chronic tic disorders (CTDs) across 9 European countries (2013–2015), focusing on associations between medication type, tic severity, and comorbid ADHD, OCD, and ODD.
32% (n=230) of participants received any pharmacological treatment: 22% received antipsychotics (mostly second-generation), 10% ADHD medications, and only 2.8% alpha-2 agonists. Medication use was highest with comorbid ADHD (54%) vs. CTD-only (23%) or CTD+OCD (26%). Those on tic-suppressing medications had significantly higher tic severity, tic-related impairment, and ADHD/ODD/obsession scores, but premonitory urge scores did not differ between medicated and unmedicated groups.
- Cross-sectional data from 2013–2015 may not reflect current prescribing, and guanfacine was only European-approved in 2015, likely inflating alpha-2 agonist underuse. - No systematic behavioral therapy data recorded, a major confound in pharmacological decision-making. - Confounding by indication: sicker patients were more likely to receive treatment, so medication–severity associations cannot be interpreted as treatment effects.
Alpha-2 agonists (clonidine, guanfacine) remain severely underused in European pediatric tic care despite guideline support, especially when ADHD co-occurs — consider them before defaulting to antipsychotics in this subgroup. Tic-suppressing medications should be reserved for cases with marked impairment, and behavioral interventions (CBIT/HRT) should be integrated regardless of medication response, since pharmacotherapy does not reliably reduce premonitory urges.
Explore related topics
